Conducted a comprehensive financial analysis of HUL's acquisition of GSK Consumer Healthcare, evaluating its strategic rationale.
Developed standalone and synergy-inclusive DCF models, alongside a relative valuation, to determine GSKCH's enterprise value. 
Assessed the financial impact of synergies and the justification of the final acquisition price.
